- After a heart attack, a multiple-pill drug regimen is essential to prevent recurrent cardiovascular events, but many patients do not continue to take recommended medications in the long term.
- Researchers conducted a clinical trial to assess the efficacy of an all-in-one pill (or polypill) strategy, compared to standard care, for the secondary prevention of cardiovascular death and complications after a heart attack.
- They found that treatment with a polypill containing aspirin, ramipril, and atorvastatin within six months after a heart attack resulted in a significantly lower risk of major adverse cardiovascular events than usual care.
According to the
During a heart attack (medically known as ‘myocardial infarction’), the blood supply to the heart is suddenly blocked, usually by a blood clot. To prevent subsequent cardiovascular complications, patients recovering from a heart attack are prescribed a combination of drugs:
- Aspirin: Prevents the formation of blood clots by stopping blood platelets from sticking together
- An angiotensin-converting–enzyme (ACE) inhibitor (e.g., ramipril) that relaxes the veins and arteries to lower blood pressure
- A statin (e.g., atorvastatin) that lowers the level of low-density lipoprotein (LDL) cholesterol in the blood
“Adherence to treatment after an acute myocardial infarction is essential for effective secondary prevention,” said Dr. José María Castellano, the study’s first author and Coordinator of Clinical Research at the Spanish National Center for Cardiovascular Research (CNIC). Yet
A potential solution for the problem of poor medication adherence is the combination of multiple drugs in a single pill, known as a ‘polypill.’
Researchers at CNIC investigated the efficacy of a polypill-based strategy in the Secondary Prevention of Cardiovascular Disease in the Elderly (SECURE) trial, led by Dr. Valentin Fuster, Ph.D., Director of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital, and General Director of CNIC.
The results of this an international randomized clinical trial were announced on August 26 at the 2022 European Society of Cardiology Congress in Barcelona, Spain, and published in The New England Journal of Medicine.
“The results of the SECURE study show that for the first time that the polypill, which contains aspirin, ramipril, and atorvastatin, achieves clinically relevant reductions in the recurrent cardiovascular events among people who have recovered from a previous heart attack because of better adherence to this simplified approach with a simple polypill, rather than taking them separately as conventional.”
– Dr. Valentin Fuster
The study enrolled 2,499 heart attack survivors across 113 centers in Spain, Italy, Germany, the Czech Republic, France, Poland, and Hungary. The average age of the study population was 76 years, and 31% of the participants were women. 77.9% had hypertension, 57.4% had diabetes, and 51.3% had a history of smoking.
The researchers randomly assigned the patients to receive the Trinomia polypill or standard therapy based on current European Society of Cardiology guidelines.
Trinomia contains aspirin (100 mg), ramipril (2.5, 5, or 10 mg), and atorvastatin (20 or 40 mg). The specific formulation used by each patient depended on their medical history and blood test results.
The researchers monitored the patients for an average of three years and examined the incidence of four major cardiovascular events: cardiovascular-related death, non-fatal heart attack, non-fatal stroke, and need for emergency coronary revascularization.
Study findings suggest that patients in the polypill group had a 9.5% incidence of these four cardiovascular events, compared to 12.7% in the standard care group. Cardiovascular-related death occurred in 48 patients (3.9%) in the polypill group, compared to 71 (5.8%) in the standard care group. Adverse events were similar between the two groups.
Self-reported medication adherence was higher among patients assigned the polypill, confirming the findings of an
When asked to comment on these findings, Dr. Eric D. Peterson, MPH, praised the researchers for conducting this clinical trial on an “important issue” but told Medical News Today he had some misgivings about the efficacy of the polypill strategy.
“[W]hile the reported differences in outcomes are quite impressive, it is somewhat difficult to wrap your head around whether they are believable. Specifically, while there were modest differences in reported adherence with polypill vs separate therapies, these did not result in any measurable differences in LDL level (a biological surrogate for statin use) or BP (a biological surrogate for lisinopriil use). Given this, not sure how the polypill resulted in huge differences in mortality…Personally, I would like to see another trial replicate these findings.”
– Dr. Eric D. Peterson
Dr. Fuster expressed optimism about the potential of the polypill strategy “to reduce the risk of recurrent cardiovascular disease and death on a global scale.”
Dr. Heinrich Taegtmeyer, D.Phil, physician-scientist and professor of medicine at McGovern Medical School, cautioned that “the polypill concept is risky unless the patients are carefully selected and monitored very closely. One-size-fits-all does not always work due to unwanted (and sometimes severe) side-effects.”
Dr. Taegtmeyer, who has been practicing cardiology and conducting National Institutes of Health (NIH)-funded basic research in cardiac metabolism for over 40 years, told MNT that “the [polypill] concept has been around for a while. It originated in the 1970s in Oxford, if I remember correctly, but never gained much traction. It comes and goes in waves. Is it the emerging awareness of [‘personalized medicine?’] An interesting debate.”
When commenting on the limitations of this study, the researchers noted that the trial was not blinded as the participants knew which treatment they were receiving. However, this should not have impacted the results since “the event adjudicators were unaware of trial-group assignments, and the outcome assessments were unbiased”.
The researchers also noted that “[w]ithdrawal and loss to follow-up may potentially bias comparisons between groups, although the frequency of withdrawal was similar in the two groups.”